Related Experiment Videos
Rheumatoid arthritis induced by alpha-interferon therapy
E Passos de Souza1, P T Evangelista Segundo, F F José
1Universidade Federal da Bahia, Salvador, Brazil.
Clinical Rheumatology
|September 1, 2001
Summary
Interferon (IFN) therapy, while treating various diseases, can rarely trigger rheumatoid arthritis (RA) in genetically predisposed individuals. This case highlights a potential link between high-dose IFN-alpha and the onset of RA symptoms.
Area of Science:
- Immunology
- Rheumatology
- Oncology
Background:
- Interferon (IFN) therapy is a common treatment for hepatitis C, myeloproliferative disorders, autoimmune diseases, and cancers.
- Rheumatoid arthritis (RA) is a prevalent autoimmune disease, but its association with IFN therapy is not well-established.
Observation:
- A 40-year-old female patient developed symmetrical polyarthritis after high-dose IFN-alpha therapy for malignant melanoma.
- Symptoms included joint pain, edema, and prolonged morning stiffness, alongside a positive rheumatoid factor and DR4 HLA phenotype.
Findings:
- The patient's presentation suggests a rare but possible adverse effect of IFN therapy, specifically the induction of rheumatoid arthritis.
- Genetic predisposition, indicated by the DR4 HLA phenotype, may play a crucial role in developing RA post-IFN treatment.
Implications:
- Interferon therapy might act as a 'trigger' for rheumatoid arthritis in susceptible individuals, leading to immune system dysregulation.
- This case underscores the importance of monitoring for autoimmune complications during IFN treatment, particularly in patients with genetic risk factors.